During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for ...

For heart failure specialists new to the cardio-oncology realm, the paper advises on patient care and what’s known thus far.

ImmPACT’s lead program, IMPT-314, is a CD19/20-targeting chimeric antigen receptor (CAR) T-cell product candidate that Lyell ...

March Biosciences, a startup spun out of Baylor College of Medicine's Center for Cell and Gene Therapy, landed a Series A ...

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack - blocking the ...

This study, being conducted in South Africa, is similar to ImmunityBio’s U.S.-based trial QUILT 3.092, a phase 1 open-label study of CD19 t-haNK as a single agent and in combination with the company’s ...

In 1893, the American Journal of the Medical Sciences reported on 10 patients whose large and hitherto incurable cancers had ...

Both agreed that there have been no trials directly comparing a BsAb therapy vs CAR T cells, so there is no definitive answer, and Landsburg was reluctant to take a hard line on reserving BsAbs until ...

MU Health Care said the new program is the only one of its kind in the region, and may help patients get care without going ...

SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET ...

Strategy for enhancing immune cell infiltration could be combined with other methods to improve cell-based immunotherapies ...